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Abstract
The epidemic due to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection has been spreading globally, 
raising increasing concerns. This public health emergency has triggered a race to find medications to improve the prognosis 
of this disease. There is currently great interest in drug repositioning to manage SARS-CoV-2 infection, that is, the evaluation 
of the potential benefits of a drug that has already been proven safe and effective in humans for other approved indications. 
As interleukin-6 (IL-6) acts as a key driver of the inflammation associated with coronavirus disease 2019 (COVID-19), IL-6 
and IL-6 receptor (IL-6R) inhibition appear to be promising targets for the treatment of COVID-19 patients. It is important 
to critically analyze the available evidence concerning the use of the available anti-IL-6 (siltuximab) and anti-IL-6R (tocili-
zumab and sarilumab) agents in COVID-19 patients, in terms of both benefit and risk. In this review, the pathogenesis of the 
cytokine storm induced by COVID-19, the role of IL-6 in this cytokine storm, the rationale for the use of anti-IL-6 agents, 
and key information on potential benefits and safety monitoring of these biologicals in COVID-19 patients is discussed.
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other researchers and clinicians who propose to repurpose 
already available treatments, due to a lack of specifically 
newly developed anti-severe acute respiratory syndrome 
coronavirus-2 (SARS-CoV-2) agents, even in the absence 
of robust scientific evidence, on the basis of clinical intui-
tion or in vitro findings only [2]. Taking the most appro-
priate decisions in such circumstances is not easy. Despite 
the comprehensible pressure to rapidly offer new therapies 
and the difficulties in carrying out clinical trials to generate 
robust scientific evidence in such a short time, a stark pre-
marketing evaluation of a drug’s benefit–risk profile seems 
to be essential to keep patients safe from ineffective and/
or high-risk drugs [3]. There is currently great interest in 
drug repurposing of anti-interleukin-6 (IL-6) agents for the 
treatment of COVID-19 patients with serious lung damage 
and elevated IL-6 levels. Nevertheless, precise recommenda-
tions may be provided only when the results of the ongoing 
clinical trials of anti-IL-6 agents in COVID-19 patients are 
published.
In this review, the pathogenesis of COVID-19 as a ration-
ale for anti-IL-6 use will be described. In addition, for all 
marketed anti-IL-6 agents, available clinical evidence of 
potential benefits, safety monitoring, and ongoing experi-
mental clinical studies in COVID-19 patients will be pre-
sented and discussed.
1 Introduction
The global coronavirus disease 2019 (COVID-19) pandemic 
has led to 5,459,528 infected patients and 345,994 deaths 
worldwide between 31 December 2019 and 26 May 2020, 
according to the European Centre for Disease Control [1]. 
In the rush to search for a treatment to improve the prog-
nosis of the disease, two contrasting currents of thoughts 
emerge: on the one hand are those who propose not to use 
medications whose risk–benefit profile has not been scien-
tifically proven in COVID-19 patients; on the other hand are 
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2  Pathogenesis of COVID‑19
Like SARS-CoV-1, SARS-CoV-2 penetrates cells as a result 
of the binding of the spike glycoprotein of the viral envelope 
to the angiotensin-converting enzyme 2 (ACE2) host cell 
surface receptor [4]. ACE2 is a type I membrane protein 
expressed on type II pneumocytes, but it can also be found 
on renal, heart, gastrointestinal, and blood vessel cells [5]. 
Once SARS-CoV-2 penetrates a cell, viral RNA genome 
is released into the cytoplasm, where sub-genomic RNA 
transcription and the replication of viral genetic material 
takes place [6]. It is important to focus on the pathogenetic 
process because it can cause severe clinical manifestations 
such as acute respiratory distress syndrome (ARDS) or mac-
rophage activation syndrome (MAS) in some patients with 
COVID-19 syndrome, possibly due to immunodysfunction 
and the uncontrolled release of pro-inflammatory cytokines 
and chemokines. Furthermore, higher levels of tumor necro-
sis factor (TNF)-α, interleukin (IL)-1, IL-10, and IL-6 have 
been detected in patients with severe COVID-19 [7].
The mechanisms leading to the uncontrolled release of 
inflammatory cytokines are still unclear, but there are at 
least two hypotheses. The first considers the rate of viral 
replication, which can cause pyroptosis (the inflamma-
tory apoptosis of epithelial and endothelial cells), and 
thus trigger the release of pro-inflammatory cytokines 
and chemokines [8]. This apoptosis also involves mac-
rophages and lymphocytes, and may cause peripheral 
lymphopenia in patients with COVID-19 syndrome [9]. 
Evidence indicates an alteration in innate immunity in 
which a pivotal role is played by INF-1, which controls 
viral replication and promotes adaptive immune responses. 
INF-1 responses to SARS-CoV and Middle East respira-
tory syndrome coronavirus (MERS-CoV) are suppressed 
because both coronaviruses have multiple strategies to 
interfere with the induction of the signal leading to INF-1 
production [10], and this weakening of the action of INF-1 
is strictly associated with the severity of the disease [11].
The second hypothesis concerns adaptive immunity and 
the role of neutralizing antibodies against the S protein of 
the virus. Animal studies of SARS-CoV have shown that 
the immunoglobulin Gs (IgGs) binding the viral S pro-
tein trigger a still-little-understood inflammatory process 
that can cause severe pulmonary lesions. Anti-S protein 
IgGs may facilitate the accumulation of pro-inflammatory 
monocytes and macrophages in the lungs by producing 
monocyte chemoattractant protein-1 (MCP-1) and IL-8, 
and this pro-inflammatory response seems to be medi-
ated by the binding of the virus/anti-S IgG complex to Fc 
receptors (FcR) on the surface of monocytes/macrophages 
[12]. Moreover, the appearance of antiviral IgGs coin-
cides with the onset of acute respiratory disease in 80% of 
patients with SARS-CoV infection [13].
The role of adaptive immunity in these circumstances 
cannot be entirely explained without also considering the 
involvement of CD8+ and CD4+ T lymphocytes, because 
cytotoxic CD8+ T cells (CTLs) secrete molecules such as 
perphorine, granzymes, and INF-γ in an attempt to eradi-
cate the virus from host cells [14], and CD4+ helper T 
lymphocytes (Th) assist cytotoxic T cells and B cells by 
producing inflammatory cytokines [15].
However, persistent SARS-CoV stimulation can deplete 
T lymphocytes in such a way as to reduce their function 
and prevent cytokine production [16]. This may be induced 
by the inhibitory cytokine IL-10, which has been detected 
in the peripheral blood of patients with COVID-19 and, in 
addition to preventing the proliferation of T lymphocytes, 
may also promote their depletion [17].
IL-6 and TNF-α also seem to be specifically involved 
in CD4+ and CD8+ T-cell depletion (which leads to 
the lymphopenia that is frequently observed in COVID-
19 patients treated in intensive care units) because their 
concentrations seem to be inversely proportional to the 
number of T lymphocytes [18]. IL-6 production can be 
induced by SARS-CoV-2 and stimulated by other cells of 
the immune system [19]. It has been shown that, during 
SARS-CoV-2 infection, CD4+ T lymphocytes are rapidly 
activated to differentiate into pathogenic Th1 cells, thus 
generating granulocyte-macrophage colony-stimulating 
factor (GM-CSF) and other pro-inflammatory cytokines 
that stimulate the activation of monocytes highly express-
ing IL-6 [20]. The complex activation of IL-6 requires the 
involvement of IL-6, the IL-6 receptor (IL-6R) and the 
gp130 co-receptor [21], but many cells that are not part 
of the immune system (including stromal and epithelial 
cells) can trigger strong inflammatory responses by means 
of trans-signaling when these three components attach to 
their membranes [22].
Key Points 
There is currently great interest in drug repurposing 
of anti-interleukin-6 (IL-6) agents for the treatment of 
COVID-19 patients, mostly in the advanced disease 
stage.
Despite the promising effects of anti-IL-6 agents, avail-
able clinical evidence is limited and only partly present 
for tocilizumab.
While waiting for more robust clinical data to support 
the efficacy of anti-IL-6 agents in COVID-19 patients, 
their potential toxicity should be carefully monitored 
and managed whenever clinicians decide to treat patients 
with these agents.
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IL-1, a pleiotropic cytokine involved in inflammatory 
processes, hematopoiesis, and fibrosis [23], also plays an 
important role in MAS and COVID-19. The release of IL-1β 
depends on the activity of the NLRP3 inflammasome, a 
receptor of the NOD family that responds to various nox-
ious stimuli including viral RNA [24]. Inflammasomes are 
large multi-molecular complexes present on innate immunity 
cells, and are best known for controlling the activation of 
caspase-1 and thus regulating the maturation of IL-1β and 
IL-18 [25]. It is becoming increasingly clear that NLRP3 
recognizes some RNA viruses by detecting the cell dam-
age or distress induced by their viroporins, which are pore-
forming transmembrane proteins [26]. Viroporins alter cell 
membrane permeability to ions by forming membrane chan-
nels [27], and a recent study has shown that the E protein 
of SARS-CoV creates channels that are permeable to  Ca2+ 
ions, and activates the NLRP3 inflammasome [28]. It is 
therefore possible that the mode of action of SARS-CoV-2 
may be similar if the concentration of IL-1 is increased in 
patients with severe COVID-19 manifestations.
In conclusion, this alteration of the immune response 
leading to an uncontrolled cytokine storm, similar to the 
cytokine release syndrome (CRS) observed with CAR-T 
immunotherapy, was associated with ARDS (even fatal) in 
COVID-19 patients. According to these observations, CRS 
is the main target on which the majority of researchers are 
focusing, with the aim of identifying an effective treatment 
for critical COVID-19 patients with severe manifestations.
3  Anti‑IL‑6 Agents
To date, it has been demonstrated that blocking IL-6 is thera-
peutically effective in various diseases, such as rheumatoid 
arthritis and Castleman’s disease, as well as in the manage-
ment of CRS following CAR T-cell infusion [29, 30]. More 
recently, as mentioned above, IL-6 was proven to be a key 
driver of the inflammation associated with COVID-19 infec-
tion [5]. As such, it has been hypothesized that monoclonal 
antibodies blocking IL-6 could help improve clinical out-
comes in COVID-19 patients with severe pneumonia. As 
explained earlier, the scientific rationale to use IL-6 inhibi-
tors is that the underlying pathophysiology of organ dam-
age (especially lungs) is caused by an amplified immune 
response and cytokine release, or ‘cytokine storm’ [31], that 
seems to be a major driver of mortality in COVID-19.
Several IL-6 inhibitors have become available on the market 
for clinical use as monoclonal antibodies targeting IL-6 (siltux-
imab) or IL-6R (tocilizumab and sarilumab) (Fig. 1). The first 
approved drug is tocilizumab [32], marketed as an intravenous 
formulation to be dosed based on body weight and, only for 
rheumatological indications, a fixed-dose subcutaneous for-
mulation. Tocilizumab has been proven to be effective either 
as monotherapy or in combination with disease-modifying 
antirheumatic drugs (DMARDs) for adult patients with mod-
erate to severe rheumatoid arthritis [33, 34] (Online Resource 
1, see electronic supplementary material [ESM]). The IL-6R 
blockade with tocilizumab was also used as first-line treatment 
for the management of CRS following CAR T-cell infusion, 
demonstrating high response rates [35, 36]. It has been shown 
that fever and tachycardia associated with CRS resolved within 
hours after administration of tocilizumab [37, 38]; resolution 
of hypotension and organ dysfunction was delayed [39]. More-
over, Alvi et al. reported that a longer lag time between CRS 
onset and tocilizumab administration was associated with an 
increase in CRS-related cardiovascular events [40]. In some 
cases, CRS refractory to tocilizumab therapy was also reported 
[41, 42]. Given the rapid clinical response to tocilizumab, it 
has become a mainstay therapy in CRS [43]. Data on tocili-
zumab for CRS treatment are still considered limited, due to 
a lack of randomized trials. However, the published studies 
describing the beneficial effects of tocilizumab on objective 
early endpoints (e.g., vital signs) [35, 36] provide substantial 
evidence for its use in life-threatening CRS.
Other marketed anti-IL-6 agents are siltuximab, licensed 
for the treatment of Castleman’s disease by the European 
Medicine Agency (EMA) in 2014 [44], and the more recently 
marketed sarilumab (2017), approved for the treatment of 
rheumatoid arthritis (Online Resource 1, see ESM). While 
tocilizumab and sarilumab act on the IL-6 receptor, siltuxi-
mab binds directly to IL-6. The affinity of sarilumab for the 
human IL-6R is greater than that of tocilizumab, and it has a 
prolonged half-life; on the other hand, the overall efficacy and 
safety of the two anti-IL-6 agents seem to be comparable [45, 
46]. Siltuximab has been less thoroughly studied in CRS treat-
ment [47], although it has been used off-label in CRS manage-
ment, especially in patients who are tocilizumab and steroid 
refractory [48].
IL-6 inhibition is a promising mechanistic pathway that has 
been explored for drug development for the treatment of a 
number of diseases such as type 1 diabetes mellitus, schizo-
phrenia, solid tumors (siltuximab and tocilizumab), uveitis, 
and sarcoidosis (sarilumab). Several clinical trials investigat-
ing anti-IL-6 agents in those diseases are currently ongoing (as 
reported in ClinicalTrials.gov and EU Clinical Trials).
4  Available Clinical Evidence and Ongoing 
Clinical Studies on Anti‑IL‑6 Agents 
for COVID‑19 Treatment
To date, evidence on beneficial effects of tocilizumab are 
derived from observational studies and case reports only, as 
summarized below. No published data regarding sarilumab 
and siltuximab in COVID-19 patients is yet available.
 S. Crisafulli et al.
A retrospective study conducted in China recruited 21 
patients diagnosed with severe or critical COVID-19 and 
treated with tocilizumab 400 mg once through intravenous 
infusion, in addition to the standard care, including lopi-
navir and methylprednisolone. The diagnosis was consid-
ered severe if any of the following conditions was met: (i) 
respiratory rate ≥ 30 breaths/min; (ii) oxygen saturation 
≤ 93%; (iii)  PaO2/FiO2 ≤ 300 mmHg. The diagnosis was 
considered critical if any of the following conditions was 
met: (i) respiratory failure requiring mechanical ventilation; 
(ii) shock; (iii) other organ failure necessitating admission to 
intensive care unit (ICU). The authors reported that the body 
temperature of all patients returned to normal values within 
the first day after receiving tocilizumab, remaining stable 
thereafter. Within the fifth day of treatment, 75% of patients 
had a reduced need for oxygen supplementation and one 
patient needed no oxygen therapy. Computed tomography 
(CT) scan showed that 90.5% of the patients had absorption 
of pulmonary lesions. Moreover, white blood cell count and 
laboratory tests demonstrated that blood lymphocytes, CRP 
and IL-6 levels returned to normal values [49]. However, 
due to the absence of a comparator group, the interpretation 
of tocilizumab-specific effects is limited and only ongoing 
experimental studies will provide more insight on the true 
effect of this drug.
Another Chinese retrospective observational study evalu-
ated the effects of tocilizumab (with doses ranging from 80 
to 600 mg per administration) in a cohort of 15 patients 
with COVID-19 [50]. Of these, two (13.3%) patients were 
moderately ill, six (40.0%) patients were seriously ill, and 
seven (46.7%) patients were critically ill. In all patients, 
CRP serum levels were high before the start of the treat-
ment with tocilizumab and they rapidly decreased after toci-
lizumab treatment. In ten patients, despite an initial increase, 
IL-6 serum levels decreased after the treatment, while a 
constant increase was observed for four patients for whom 
Fig. 1  SARS-CoV-2-induced cytokine storm and mechanism of 
action of anti-IL-6 and anti-IL-6R drugs. IL-6/IL-6R signaling path-
way: the binding of IL-6 to its soluble (sIL-6R) and membrane-bound 
receptors (mIL-6R) determines their dimerization, resulting in the 
juxtaposing of receptor-associated JAKs. The JAKs subsequently 
undergo auto-phosphorylation and/or transphosphorylation on target 
tyrosine residues. The activation of JAKs results in the propagation 
of the cytokine-mediated signal and finally determines the activa-
tion of transcription factors, such as the STATs. The activated STATs 
dimerize and translocate to the cell nucleus to induce or suppress tar-
get genes [62]. Anti-IL-6 and anti-IL-6R agents inhibit sIL-6R and 
mIL-6R-mediated signaling. IL-6 interleukin 6, IL-6R interleukin 
6 receptor, JAK Janus kinase, SARS-CoV-2 severe acute respiratory 
syndrome coronavirus-2, STAT Signal Transducer and Activator of 
Transcription
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tocilizumab was ineffective. The authors suggested using 
tocilizumab in patients affected by COVID-19 and at risk 
of developing cytokine storms and recommended repeated 
doses (2–3 doses with a frequency of daily, every other day, 
or every 3 days) for critically ill patients with elevated IL-6 
serum levels.
Further evidence of the effectiveness of tocilizumab on 
COVID-19 patients emerges from a case report of a 42-year-
old male affected by metastatic sarcomatoid clear cell renal 
cell carcinoma who was hospitalized for fever [51]. On the 
sixth day, the real-time polymerase chain reaction (RT-
PCR) assay proved him positive for SARS-CoV-2. The 
patient was initially treated with lopinavir/ritonavir, which 
was ineffective, leading him to develop sudden dyspnea and 
an increased need for oxygen supplementation. The patient 
was subsequently treated with two intravenous doses of 
tocilizumab 8 mg/kg. A clinical improvement was rapidly 
observed and the oxygen consumption also decreased. The 
treatment was fully withdrawn on day 12. The clinical 
improvement was also confirmed by CT scan that showed a 
partial regression of the pulmonary infiltration and by labo-
ratory examinations demonstrating a decrease in serum CRP 
levels in 4 days. The patient fully recovered from COVID-19 
symptoms on day 12.
More recent data on the effectiveness of tocilizumab in 
COVID-19 patients come from an Italian observational 
study that enrolled 100 patients with confirmed COVID-
19 pneumonia and ARDS requiring ventilatory support, 
from March 9 until March 20, 2020. Patients were treated 
with tocilizumab at a dosage of 8 mg/kg by two consecu-
tive intravenous infusions every 12 h. Based on clinical 
response, a third infusion was optional. Improvement in 
ADRS was assessed at 24–72 h and 10 days after administra-
tion of tocilizumab, using the ‘Brescia-COVID respiratory 
severity scale’ (BCRSS 0–8, with higher scores indicating 
higher severity). Of the 100 treated patients, 43 received 
tocilizumab in the ICU, while 57 received it in the general 
ward. Overall, at 10 days, the respiratory condition was 
improved or stabilized in 77 patients (77%), of whom 61 
(79.2%) showed a significant reduction in lung lesions and 
15 (19.5%) were discharged from the hospital [52]. However, 
a limitation of this study is the lack of a control group.
As regards experimental investigations, 49 clinical trials 
of anti-IL-6 drugs in COVID-19 patients are currently ongo-
ing, as registered on ClinicalTrials.gov and the EU Clini-
cal Trials Register (updated to 21 May 2020). Of these, 36 
(73.5%) are aimed at investigating tocilizumab, 15 (30.6%) 
sarilumab, and 3 (6.1%) siltuximab. The majority of these 
studies are phase II clinical trials (N = 23; 46.9%), followed 
by phase III clinical trials (N = 10; 20.4%). The remain-
ing studies are phase II/III clinical trials (N = 6; 12.3%), 
phase IV clinical trials (N = 3; 6.1%), observational studies 
(N = 6; 12.3%) and phase I clinical trials (N = 1; 2.0%). 
Only nine (18.4%) of them are sponsored by pharmaceutical 
companies. Most of these studies are conducted in European 
(N = 33; 67.3%) or American (N = 14; 28.6%) countries. 
The estimated enrollment ranges from 20 patients in the 
smallest study to 12,000 patients in the largest study, which 
is evaluating several different pharmacological interventions 
(Online Resource 2, see ESM).
Although clinical evidence is still sparse, in March 2020, 
the Chinese National Medical Products Administration 
(NMPA) approved tocilizumab for the treatment of patients 
affected by COVID-19 with serious lung injury and ele-
vated IL-6 levels [53]. Several national drug agencies have 
approved anti-IL-6 agents for compassionate use. Accord-
ingly, the Society for Immunotherapy of Cancer (SITC) 
issued a statement requesting to maximize the availability 
of anti-IL-6/IL-6R drugs for compassionate use to treat criti-
cally ill hospitalized patients with COVID-19 [54].
5  Monitoring of Safety of Anti‑IL‑6 Agents
The use of anti-IL-6 drugs is associated with an increased 
risk of severe infections (e.g., tuberculosis); accordingly, 
monitoring for early detection of infections [55–58] is rec-
ommended. Other common adverse reactions of anti-IL-6 
agents include increased transaminase blood levels (tocili-
zumab and sarilumab) and cytopenias [56–59]. The mecha-
nism underlying anti-IL-6-induced neutropenia is unclear 
and it could be related to a margination effect rather than 
myelosuppression [60]. Serious drug-induced liver injury, 
including acute liver failure, hepatitis, and jaundice, have 
been observed with tocilizumab [56–58].
A recent review of literature aiming to assess the effi-
cacy of tocilizumab for the treatment of CRS carried out 
a retrospective analysis of pooled data from prospective 
clinical trials of CAR T-cell therapies for hematological 
malignancies. No adverse reactions to tocilizumab in the 
patients treated for CRS were reported. However, as con-
firmed by authors, there were no specific assessments for 
the safety of tocilizumab (e.g., infusion reactions, exac-
erbation of CAR T cell-induced neurotoxicity, prolonged 
neutropenia) in clinical trials analyzed. Data reviewed 
were considered insufficient to assess the overall activity 
of tocilizumab for treatment of CRS, and further post-
marketing studies to confirm the safety of tocilizumab in 
patients with CRS are required. Nevertheless, the risks 
associated with tocilizumab seem to be outweighed by the 
potential benefits observed in patients with severe or life-
threatening CRS and potentially for COVID-19 patients 
[61].
Hypersensitivity reactions, erythema, pruritus, and 
edema are adverse reactions occasionally observed 
after administration of anti-IL-6 drugs. In case of 
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hypersensitivity reactions, administration of anti-IL-6 
agents should be immediately stopped [56–58].
6  Conclusions
The pathological mechanisms leading to severe clinical 
manifestations in COVID-19 patients have not been fully 
determined. It has been demonstrated that serum levels 
of IL-6 are significantly elevated in these patients, thus 
leading to an excessive immune response and autoim-
mune injury. Except for tocilizumab in China, no anti-
IL-6 drugs have been specifically approved for COVID-19 
treatment so far. To shorten timeframes and reduce costs, 
repurposing of drugs that have already proven to be safe 
and effective in humans in other indications could be a 
valid option in such difficult circumstances, while await-
ing more experimental clinical evidence on potentially 
eligible drugs for COVID-19 treatment to be generated. 
There is a strong rationale for the use of anti-IL-6 agents in 
COVID-19 patients, mostly in the advanced disease stage. 
However, despite their promising effects, available clinical 
evidence is limited and only partly present for tocilizumab. 
Nevertheless, several phase II and III clinical studies of 
anti-IL-6 are ongoing and will eventually shed light on 
the beneficial effects of these drugs in COVID-19. While 
awaiting the preliminary results of these studies, the poten-
tial toxicity of anti-IL-6 should be carefully monitored and 
managed, whenever clinicians decide to treat patients with 
anti-IL-6 agents.
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